NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCOCHICAGO, May 31, 2026 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as Rapid Oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO 2026). ASCO is one of the leading global oncology conferences. With over 8,500 submissions, abstracts selected for oral presentation represents studies of significant scientific and clinical interests.
NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant GliomaSINGAPORE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy for malignant glioma. The data were presented at the ESMO Asia Congress 2025, December 5–7 in Singapore.
